Table 2.
Cox regression analyses of baseline predictors of TTR according to postoperative recurrence period
| Variable | TTR within 5 years after resection |
TTR beyond 5 years after resection |
||||||
|---|---|---|---|---|---|---|---|---|
| Unadjusted hazard ratio (95% CI) | p value | Adjusted hazard ratio* (95% CI) | p value | Unadjusted hazard ratio (95% CI) | p value | Adjusted hazard ratio† (95% CI) | p value | |
| Male gender | 1.137 (0.956–1.352) | 0.146 | 1.143 (0.957–1.366) | 0.141 | 1.706 (0.968–3.009) | 0.065 | 1.746 (0.985–3.095) | 0.056 |
| Age >50 years | 0.966 (0.832–1.122) | 0.654 | 0.960 (0.607–1.518) | 0.861 | ||||
| HBV infection | 0.927 (0.775–1.109) | 0.408 | 1.324 (0.575–3.047) | 0.509 | ||||
| Serum AST, IU/L | ||||||||
| ≤40 | 1.0 (Ref) | 0.460 | 1.0 (Ref) | 0.220 | ||||
| 41–80 | 1.080 (0.936–1.247) | 0.290 | 1.499 (0.925–2.428) | 0.100 | ||||
| >80 | 0.960 (0.772–1.195) | 0.716 | 1.430 (0.697–2.935) | 0.329 | ||||
| Serum ALT, IU/L | ||||||||
| ≤40 | 1.0 (Ref) | 0.924 | 1.0 (Ref) | 0.564 | ||||
| 41–80 | 1.003 (0.862–1.167) | 0.969 | 1.252 (0.767–2.044) | 0.368 | ||||
| >80 | 1.046 (0.836–1.310) | 0.692 | 1.377 (0.589–3.215) | 0.460 | ||||
| Platelet count < 100K/mm3 | 1.133 (0.925–1.387) | 0.227 | 1.491 (0.788–2.824) | 0.220 | ||||
| Serum AFP ≥200 ng/mL | 1.427 (1.234–1.650) | <0.001 | 1.243 (1.069–1.445) | 0.005 | 0.958 (0.591–1.553) | 0.862 | ||
| Maximal tumor diameter, cm | ||||||||
| <3 | 1.0 (Ref) | <0.001 | 1.0 (Ref) | <0.001 | 1.0 (Ref) | 0.422 | ||
| 3–5 | 1.319 (1.132–1.537) | <0.001 | 1.304 (1.116–1.524) | 0.001 | 1.274 (0.794–2.043) | 0.316 | ||
| >5 | 1.970 (1.661–2.337) | <0.001 | 2.092 (1.735–2.522) | <0.001 | 0.825 (0.399–1.704) | 0.602 | ||
| Tumor multiplicity | 1.651 (1.357–2.009) | <0.001 | 1.474 (1.206–1.802) | <0.001 | 1.567 (0.721–3.408) | 0.257 | ||
| Microvascular invasion | 1.643 (1.407–1.919) | <0.001 | 1.390 (1.180–1.637) | <0.001 | 1.148 (0.590–2.230) | 0.685 | ||
| Capsular invasion | 1.966 (1.565–2.470) | <0.001 | 1.731 (1.374–2.181) | <0.001 | 0.632 (0.272–1.471) | 0.287 | ||
| Moderately or poorly differentiated tumor | 1.272 (1.107–1.463) | 0.001 | 1.151 (0.997–1.329) | 0.056 | 1.102 (0.678–1.793) | 0.694 | ||
| METAVIR fibrosis stage | ||||||||
| F0 | 1.0 (Ref) | 0.010 | 1.0 (Ref) | <0.001 | 1.0 (Ref) | 0.015 | 1.0 (Ref) | 0.013 |
| F1 | 1.269 (0.911–1.767) | 0.159 | 1.524 (1.090–2.131) | 0.014 | 1.771 (0.383–8.199) | 0.465 | 1.678 (0.362–7.775) | 0.508 |
| F2 | 1.269 (0.912–1.766) | 0.157 | 1.561 (1.115–2.184) | 0.009 | 1.975 (0.433–9.016) | 0.380 | 1.943 (0.426–8.873) | 0.391 |
| F3 | 1.688 (1.072–2.657) | 0.024 | 1.847 (1.165–2.928) | 0.009 | 1.708 (0.155–18.844) | 0.662 | 2.210 (0.198–24.723) | 0.520 |
| F4 | 1.535 (1.138–2.069) | 0.005 | 2.141 (1.569–2.923) | <0.001 | 4.150 (1.012–17.008) | 0.048 | 4.110 (1.003–16.847) | 0.049 |
TTR, time to first recurrence; CI, confidence interval; HBV, hepatitis B virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fetoprotein.
*
Adjusted for male gender, serum AFP level, maximal tumor diameter, tumor multiplicity, microvascular invasion, capsular invasion, moderately or poorly differentiated tumor, and METAVIR fibrosis stage, which were variables meeting a prechosen p value (i.e., <0.2) in univariate analyses for TTR.
†
Adjusted for male gender and METAVIR fibrosis stage, which were variables meeting a prechosen p value (i.e., <0.2) in univariate analyses for TTR.